Arteris, Inc.
For the period ended Dec 31, 2025. Filed Feb 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
(a) Not applicable
(b) Insider Trading Arrangements
On November 7, 2025, Atiq Raza, Director, as the trustee of Saiyed Atiq Raza and Nandini Saraiya 2012 Revocable Trust Dated November 26, 2012, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 610,839 shares of the Company’s common stock until December 31, 2026.
On December 12, 2025, K. Charles Janac, Chief Executive Officer (CEO), adopted a single Rule 10b5-1 trading arrangement, in his individual capacity and in his capacity as manager of Bayview Legacy, LLC, that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to an aggregate of 1,068,528 shares of the Company’s common stock until June 30, 2027, consisting of up to 68,528 shares held by Mr. Janac and up to 1,000,000 shares held by Bayview Legacy, LLC.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.